Literature DB >> 34014545

Targeting Metabolic Cross Talk Between Cancer Cells and Cancer-Associated Fibroblasts.

Jin G Jung1, Anne Le2,3.   

Abstract

Although cancer has classically been regarded as a genetic disease of uncontrolled cell growth, the importance of the tumor microenvironment (TME) [1, 2] is continuously emphasized by the accumulating evidence that cancer growth is not simply dependent on the cancer cells themselves [3, 4] but also dependent on angiogenesis [5-8], inflammation [9, 10], and the supporting roles of cancer-associated fibroblasts (CAFs) [11-13]. After the discovery that CAFs are able to remodel the tumor matrix within the TME and provide the nutrients and chemicals to promote cancer cell growth [14], many studies have aimed to uncover the cross talk between cancer cells and CAFs. Moreover, a new paradigm in cancer metabolism shows how cancer cells act like "metabolic parasites" to take up the high-energy metabolites, such as lactate, ketone bodies, free fatty acids, and glutamine from supporting cells, including CAFs and cancer-associated adipocytes (CAAs) [15, 16]. This chapter provides an overview of the metabolic coupling between CAFs and cancer cells to further define the therapeutic options to disrupt the CAF-cancer cell interactions.

Entities:  

Keywords:  Cancer therapy; Cancer-associated adipocytes; Cancer-associated fibroblasts; Metabolism; Metabolites; Tumor microenvironment

Mesh:

Year:  2021        PMID: 34014545     DOI: 10.1007/978-3-030-65768-0_15

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  80 in total

Review 1.  Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation.

Authors:  B Elenbaas; R A Weinberg
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

Review 2.  Tumor angiogenesis: therapeutic implications.

Authors:  J Folkman
Journal:  N Engl J Med       Date:  1971-11-18       Impact factor: 91.245

Review 3.  Putting tumours in context.

Authors:  M J Bissell; D Radisky
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

4.  Endostatin: an endogenous inhibitor of angiogenesis and tumor growth.

Authors:  M S O'Reilly; T Boehm; Y Shing; N Fukai; G Vasios; W S Lane; E Flynn; J R Birkhead; B R Olsen; J Folkman
Journal:  Cell       Date:  1997-01-24       Impact factor: 41.582

5.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent.

Authors:  Karin E de Visser; Lidiya V Korets; Lisa M Coussens
Journal:  Cancer Cell       Date:  2005-05       Impact factor: 31.743

6.  Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.

Authors:  K J Kim; B Li; J Winer; M Armanini; N Gillett; H S Phillips; N Ferrara
Journal:  Nature       Date:  1993-04-29       Impact factor: 49.962

Review 7.  Basement membranes: structure, assembly and role in tumour angiogenesis.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

Review 8.  Tumor stroma and regulation of cancer development.

Authors:  Thea D Tlsty; Lisa M Coussens
Journal:  Annu Rev Pathol       Date:  2006       Impact factor: 23.472

Review 9.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

10.  Cdc42EP3/BORG2 and Septin Network Enables Mechano-transduction and the Emergence of Cancer-Associated Fibroblasts.

Authors:  Fernando Calvo; Romana Ranftl; Steven Hooper; Aaron J Farrugia; Emad Moeendarbary; Andreas Bruckbauer; Facundo Batista; Guillaume Charras; Erik Sahai
Journal:  Cell Rep       Date:  2015-12-17       Impact factor: 9.423

View more
  4 in total

Review 1.  Metabolic Regulation of Fibroblast Activation and Proliferation during Organ Fibrosis.

Authors:  Sudan Wang; Yan Liang; Chunsun Dai
Journal:  Kidney Dis (Basel)       Date:  2022-03-03

2.  Epigallocatechin‑3‑gallate hinders metabolic coupling to suppress colorectal cancer malignancy through targeting aerobic glycolysis in cancer‑associated fibroblasts.

Authors:  Shuhai Chen; Masaaki Nishi; Yuji Morine; Mitsuo Shimada; Takuya Tokunaga; Hideya Kashihara; Chie Takasu; Shinichiro Yamada; Yuma Wada
Journal:  Int J Oncol       Date:  2022-01-14       Impact factor: 5.650

Review 3.  Dynamic Cancer Cell Heterogeneity: Diagnostic and Therapeutic Implications.

Authors:  Valerie Jacquemin; Mathieu Antoine; Geneviève Dom; Vincent Detours; Carine Maenhaut; Jacques E Dumont
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

Review 4.  Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance.

Authors:  Pradip De; Jennifer Aske; Raed Sulaiman; Nandini Dey
Journal:  Cancers (Basel)       Date:  2022-03-16       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.